^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Published date:
01/28/2023
Excerpt:
This was a single-center retrospective study of adult patients diagnosed with first recurrence GBM and received pembrolizumab or nivolumab with or without concurrent bevacizumab….Median overall survival (mOS) from initial diagnosis was 24.5 months (range 10-42). mOS from onset of ICI was 10 months (range 1-31) with 75% surviving > 6 months and 46% > 12 months. Additional IHC analysis on tumors from eight patients demonstrated a trend of longer survival after ICI for those with elevated PD-L1 expression.
DOI:
10.1007/s00262-023-03381-y
